Doctor's Desk
WorkWise Newsletter Archive
www.osh.net

November 29, 2001

Planning for Bioterrorism

A preview of selected text from the upcoming book: “Physical and Biological Hazards of the Workplace, Second Edition”

By Peter H. Wald, MD and Gregg M. Stave, MD

Concerns about biological warfare and bioterrorism have existed for several decades, and have been heightened by the horrific events of September 11, 2001 , and their aftermath.

Several countries are known to have had biological warfare programs and stocks of agents are known to exist. At least 35 agents and organisms have been classified as possible bioterrorism concerns. The most widely discussed are anthrax, botulism, plague, tularemia, and smallpox (Table 20-5.). An epidemic of anthrax occurred in the former Soviet Union following an accidental release from a military facility in Sverdlovsk in 1979. As of this writing, in October 2001, there had been more than a dozen exposures to anthrax sent through the mail in the US , resulting in several cases of cutaneous anthrax and one fatality due to inhalation anthrax. These episodes have led to heightened fears about the possibility of further small and also large-scale bioterroism activities.

While publicized incidents of bioterrorism lead to significant fears, it should be kept in mind that the actual risk of being involved in an event is extremely small. The dissemination of large quantities of bioterroism agents and organisms fortunately has many significant technical challenges.

A prudent response to concerns involves different actions for individuals, professionals, and organizations. In general, people should be reassured that their personal risk is very low, and that they should take reasonable precautions in everyday life. This includes not handling suspicious looking mail and packages, and accessing their local emergency response system as needed. The practices of hoarding antibiotics or using antibiotics without a medical diagnosis should be discouraged.

For the medical and emergency response community, there is a need to learn to recognize the signs and symptoms of bioterrorism agents and organisms (Table 20-5.). This is of special concern because many of these diseases are otherwise uncommon, or, as in the case of smallpox, have not been seen for decades.

Significant improvements in the public health infrastructure are needed to enhance readiness for bioterrorism. Increased funding of these activities is likely in light of the events of 2001.

The animal care community also plays a role in surveillance, since some of the organisms involved are animal pathogens. Veterinarians, farmers, and others who work with and care for animals need to recognize potential public health implications of certain problems seen in animals.

Organizations and companies that handle mail and packages need to develop prudent handling procedures to recognize and isolate suspicious items. Medical, maintenance, safety, and security staffs, and emergency response personnel should receive appropriate training.

Finally, concerns about bioterrorism should be kept in perspective in the context of the everyday risks to life and health. Most preventable morbidity and mortality is due to addictions (especially tobacco) and modifiable lifestyle factors, and treatable diseases and risk factors. Individuals, healthcare personnel and health systems should maintain and increase the focus on these more mundane issues, as they will ultimately have the greatest impact on life and health.

Table 20-5. Potential Biological Warfare Agents



Disease

Incubation

Symptoms

Signs

Diagnostic tests

Transmission and Precautions

Treatment

(Adult dosage)

Prophylaxis

Inhaled Anthrax

2-6 days

Range: 2 days to 8 weeks

Flu-like symptoms

Respiratory distress

Widened mediastinum on chest X-ray (from adenopathy)

Atypical pneumonia

Flu-like illness followed by abrupt onset of respiratory failure

Gram stain (“boxcar” shape)

Gram positive bacilli in blood culture

ELISA for toxin antibodies to help confirm

Aerosol inhalation

No person-to-person transmission

Standard precautions

Mechanical ventilation

Antibiotic therapy

Ciprofloxacin 400 mg iv q 8-12 hr

Doxycycline 200 mg iv initial, then 100 mg iv q 8-12 hr

Penicillin 2 mil units iv q 2 hr

   -- possibly add gentamicin

Ciprofloxacin 500 mg po bid or doxycycline 100 mg po bid for ~ 8 weeks  (shorter with  anthrax vaccine)

FDA-approved vaccine: administer after exposure if available

Botulism

12-72 hours

Range:

2 hrs – 8 days

Difficulty swallowing or speaking (symmetrical cranial neuropathies)

Symmetric descending weakness

Respiratory dysfunction

No sensory dysfunction

No fever

Dilated or un-reactive pupils

Drooping eyelids (ptosis)

Double vision (diplopia)

Slurred speech (dysarthria)

Descending  flaccid paralysis

Intact mental state

Mouse bioassay in public health  laboratories (5 – 7 days to conduct)

ELISA for toxin

Aerosol inhalation

Food ingestion

No person-to-person transmission

Standard precautions

Mechanical ventilation

Parenteral nutrition

Trivalent botulinum antitoxin available from State Health Departments and CDC

Experimental vaccine has been used in laboratory workers

Plague

1-3 days by inhalation

Sudden onset of fever, chills, headache, myalgia

Pneumonic: cough, chest pain, hemoptysis

Bubonic : painful lymph nodes

Pneumonic:  Hemoptysis;

  radiographic pneumonia --

    patchy, cavities, confluent consolidation

Bubonic:   typically painful, enlarged lymph nodes in groin, axilla, and neck

Gram negative coccobacilli and bacilli in sputum, blood, CSF, or bubo aspirates (bipolar, closed “safety pin” shape on Wright, Wayson's stains)

ELISA, DFA, PCR

Person-to-person transmission  in pneumonic forms

Droplet precautions until patient treated for at least three days

Streptomycin 30 mg/kg/day in two divided doses x 10 days

Gentamicin 1-1.75 mg/kg iv/im q 8 hr

Tetracycline 2-4 g per day

Asymptomatic contacts; or potentially exposed

Doxycycline 100 mg po q 12 hr x 7 days

Ciprofloxacin 500 mg po

Tetracycline 250 mg po q 6 hr x 7 days

Vaccine production discontinued

Tularemia

“pneumonic”

2-5 days

Range:

1-21 days

Fever, cough, chest tightness, pleuritic pain

Hemoptysis rare

Community-acquired, atypical pneumonia

Radiographic: bilateral patchy pneumonia with hilar adenopathy (pleural effusions like TB)

Diffuse, varied skin rash

May be rapidly fatal

Gram negative bacilli in blood culture on  BYCE (Legionella) cysteine- or S-H-enhanced media

Serologic testing  to confirm: ELISA, microhemagglutination

DFA for sputum or local discharge

Inhalation of agents

No person-to-person transmission but laboratory personnel at risk

Standard precautions

Streptomycin 30 mg/kg/day IM divided bid for 10-14 days

Gentamicin 3-5 mg/kg/day iv in equal divided shoulders x 10-14 days

Ciprofloxacin possibly effective 400 mg iv q 12 hr (change to po after clinical improvement) x 10-14 days

Ciprofloxacin 500 mg po q 12 hr x 2 wks

Doxycycline 100 mg po q 12 hr x 2 wks

Tetracycline 250 mg po q 6 hr

Experimental live vaccine

Smallpox

12-14 days

Range:7-17 days

High fever and myalgia;

itching; abdominal pain; delirium

Rash on face, extremities, hands, feet; confused with chickenpox which has less uniform rash

Maculopapular then vesicular rash --  first on extremities (face, arms, palms, soles, oral mucosa)

Rash is synchronous on various segments of the body

Electron microscopy of pustule content

PCR

Public health  lab for confirmation

Person-to-person transmission

Airborne precautions

Negative pressure

Clothing  and surface decontamination

Supportive care

Vaccinate care givers

Vaccination (vaccine available from CDC)

Courtesy of Michael Hodgson, M.D., http://occenvmed.net/biocard16.doc , accessed 10/16/01

Bioterrorism Websites

            http://www.bt.cdc.gov

http://www.hopkins-biodefense.org

http://biotech.law.umkc.edu/blaw/govdocs.htm

http://biotech.law.umkc.edu/blaw/Bioterror.htm

http://www.ama-assn.org/ama/pub/category/6206.html

http://www.usamriid.army.mil/education/bluebook.html

http://miemss.umaryland.edu/WMDSupplement.pdf

http://www.nbc-med.org

Exclusive Offer for WorkCare Users--Receive Free Shipping

Enter This Code 13911 in the "Product Search" Box of our publishing partner for Free

Shipping Charges on

“Physical and Biological Hazards of the Workplace, Second Edition”
by Peter H. Wald, MD and Gregg M. Stave, MD

NEW! Now extensively updated and expanded, this practical "how-to" reference provides an overview including basic information on either the physical type or underlying biology of workplace hazards. The new edition includes updated references and latest research. Biological agents are covered in equal depth, from the fundamentals of microbiology and infectious disease, to the specific details of organic hazards like wood dust and endotoxins. Release date, December 2001. Hardcover, 600 pages.